Cell BiologybioRxiv
Galactose-modified duocarmycin prodrugs as senolytics
A. Guerrero, R. Guiho, N. Herranz…·J. Gil
This study develops galactose-modified duocarmycin prodrugs that selectively kill senescent cells by targeting lysosomal β-galactosidase, showing therapeutic potential for age-related diseases.
DOI 10.1111/acel.13133